Drugmaker Biogen said on Tuesday it intends to spin off its hemophilia drug business as an independent, publicly traded company. » Read More
U.S. stocks closed lower Thursday, with telecoms leading declines amid the latest batch of earnings.
Jim Cramer goes off the charts to determine if the biotech sector could come roaring back.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
Check out the companies making headlines after the bell Tuesday: Nike, Gilead, Five Below and more.
Year Up is a nonprofit that offers low-income urban youths six months of intensive training and a six-month internship. Here's why it's working.
Evercore ISI's Mark Schoenebaum weighs in on if the biotech sector has seen bottom
The number one biotech analyst Mark Schoenebaum, Evercore ISI pharma analyst, weighs in on the selloff in the space, and which stocks have the potential to go higher this year.
During the 2016 Super Bowl, Denver Broncos cornerback Aqib Talib will don a high-tech helmet to safeguard against head injury.
U.S. stocks closed more than 1 percent lower Wednesday, despite higher oil prices, as disappointing quarterly reports weighed and the Fed statement renewed concerns about global economic growth.
U.S. stock index futures pointed to a lower open on Wednesday as low oil prices and earnings reports weighed on stocks ahead of the expected release of the Fed meeting statement in the afternoon.
Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.
While the biotech sector has been under fire for high drug prices, Biotech CEO says that it brings innovations.
Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
“Mad Money” host Jim Cramer is telling investors which stock is headed higher for the long-term.
Jim Cramer prepares investors for the biotech group to come roaring back in 2016, and shares his top picks.
Jim Cramer looks at the stock market like a card game, and investors just aren't dealing with the cards they have right now.
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
Jim Cramer says this week was the most amazing transformation he has ever seen before. But can the bull continue to dance?